What role do combination therapies play in cancer treatment?

Combination therapies are vital in cancer treatment because they help overcome immune resistance, improving the effectiveness of treatments. They integrate various therapeutic strategies to enhance patient outcomes, especially in complex cases where single-agent therapies might not suffice.

How are CAR-T technologies evolving in immuno-oncology?

CAR-T technologies are advancing to broaden their applications and address challenges like immune cell exhaustion. Innovations are focused on improving design and delivery methods to enhance durability and specificity, which are crucial for successful immuno-oncology therapies.

Why is the tumor microenvironment important in cancer treatment research?

The tumor microenvironment plays a critical role in cancer treatment research because it can influence the response to therapies. Understanding and modeling this environment accurately in preclinical studies help researchers develop more precise treatments that consider these interactions, potentially leading to higher success rates.

Shaping the Future of Cancer Care Through I...

Shaping the Future of Cancer Care Through Immuno-Oncology

Combination therapies and emerging cell-based treatments are reshaping how oncologists tackle cancer on a cellular level. Immuno-oncology continues to drive innovation with recent FDA approvals and advancements in CAR-T and bispecific antibodies. Experts explore strategies to combat immune cell exhaustion and tumor microenvironment challenges.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Crown Bioscience on MarketScale.

By Healthcare · April 19, 2025, 1:05 AM UTCCar-t TherapiesCombination TherapiesCrown BioscienceCrowncast

Key takeaways

Combination therapies are crucial in overcoming immune resistance.

Advancements in CAR-T technologies are expanding treatment possibilities.

The tumor microenvironment significantly impacts therapy success.

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed by the tumor microenvironment and immune cell exhaustion to increase therapeutic success rates.

How can scientists and biotech innovators harness the immune system more effectively to combat cancer—and what does the next generation of immuno-oncology look like?

On this episode of Crowncast by Crown BioScience, host Jonny McMichael welcomes Gera Goverse, Director of Immuno-Oncology at Crown BioScience, for a deep dive into the scientific advances and strategic considerations shaping immuno-oncology today. From bispecifics and checkpoint inhibitors to personalized and allogeneic CAR-T therapies, they explore the complexity of immune response modeling, the need for combination therapies, and how the tumor microenvironment impacts treatment outcomes.

Key discussion points from this episode:

The rise of combination therapies and their role in overcoming immune resistance
Emerging innovations in CAR-T design to address exhaustion and broaden application
The critical importance of tumor microenvironment and model precision in preclinical research

About the Guest

Gera Goverse is an accomplished immunologist with a PhD from Amsterdam UMC and a postdoctoral fellowship at KU Leuven. She has over a decade of experience in immunology and oncology, having transitioned from academia to biotech, where she now leads the immuno-oncology efforts at Crown BioScience Netherlands following their merger with organoid research CRO Ocello.